A day after Ophthalix Inc., of Petach Tikvah, Israel, reported that CF101, an A3 adenosine receptor (A3AR) agonist licensed from parent company Can-Fite Biopharma Ltd., failed to meet primary and secondary efficacy endpoints in a Phase III study in moderate-to-severe dry eye syndrome, Ophthalix is planning a retrospective analysis of its Phase III dry eye syndrome study data to determine if there is a correlation between the A3AR biomarker and patients’ response to CF101.